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SUMMARY
The favorable outcome of the treatment of a disease is influenced by the adherence to therapy. Our objective was to assess factors 
associated with adherence to treatment of patients included in a clinical trial of equivalence between the standard and alternative 
treatment schemes with meglumine antimoniate (MA) in the treatment of cutaneous leishmaniasis (CL), in the state of Rio de Janeiro. 
Between 2008 and 2011, 57 patients with CL were interviewed using a questionnaire to collect socioeconomic data. The following 
methods were used for adherence monitoring: counting of vial surplus, monitoring card, Morisky test and modified Morisky test 
(without the question regarding the schedule); we observed 82.1% (vial return), 86.0% (monitoring card), 66.7% (Morisky test) and 
86.0% (modified Morisky test) adherence. There was a strong correlation between the method of vial counting and the monitoring 
card and modified Morisky test. A significant association was observed between greater adherence to treatment and low dose of MA, 
as well as with a lower number of people sleeping in the same room. We recommend the use of the modified Morisky test to assess 
adherence to treatment of CL with MA, because it is a simple method and with a good performance, when compared to other methods. 
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INTRODUCTION
Cutaneous Leishmaniasis (CL) is a disease caused by a protozoan of 
the Leishmania genus and transmitted by the bites of female Phlebotomus 
(Dipteran, Psychodidae, Phlebotominae). In the state of Rio de Janeiro, 
Brazil, CL is caused mainly by L. (Viannia) braziliensis1,28.
Pentavalent antimonials have been used for decades and are still 
the first drug of choice in the treatment of leishmaniasis, despite its 
known toxicity, difficult handling and not fully understood mechanism 
of action9,10.
Meglumine antimoniate (MA) is supplied in 5 mL vials containing 
1.5g N-methylglucamine, equivalent to 405 mg of pentavalent antimony 
(Sb5+)34. It can be administered parentally (IM or IV). The therapeutic 
schemes may vary in duration, total dose and daily dose. Poor therapeutic 
response has been described29.
In Brazil, the Ministry of Health18 recommends a dose of 10-20 mg 
Sb5+/kg/day, over 20 days, taking into consideration a maximum limit 
of three vials per day, to treat CL patients with MA.
Clinical studies in Rio de Janeiro, with long-term patient monitoring, 
have suggested that both, the use of regular schemes with low doses 
(5 mg Sb5+/kg/day) administered systemically and the intralesional 
therapy with MA18,22,30,31, can be effective schemes, achieving cure 
rates similar to those obtained with higher doses, although with lower 
toxicity, greater ease of implementation and lower cost27. Schemes 
with intermittent doses of 15 mg Sb5+ obtained greater adherence and 
effectiveness, when compared with continuous schemes2. 
According to the World Health Organization (WHO)35, adherence 
may be defined as the degree of a person’s acceptance of the 
recommendations of the practitioner or other health care providers, 
which include taking drugs, following a diet, behavioral changes and 
attending appointments previously made. However, since it demands the 
participation of the patient, a good patient - health provider relationship 
should be established24. 
The methods adopted to assess adherence to treatment may be 
classified as direct or indirect methods, but no method is considered 
the gold standard for this evaluation6. The direct methods quantify the 
drug or the metabolite in biological fluids and/or test specimens11,33. The 
indirect methods assess adherence through interviews with patients and 
counting the drugs that the patient still has remaining, which tends to be 
a method more prone to error caused by the patient11,33.
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Adherence to therapy is a phenomenon subject to many factors that 
directly affect the patient24,31. Adherence questionnaires are methods 
used to assess results. The structured interview is one of the most used 
methods, because of its low cost and accessible implementation24. Some 
forms used in adherence interviews are found in literature, such as the 
Morisky test19,20. 
The WHO35 mentions several factors that can influence adherence 
to therapy: socioeconomic and cultural factors, those related to health 
providers and services, factors in relation to treatment and the patient. 
The objective of the present study is to assess factors associated 
with adherence to patients included in a clinical trial with MA, in the 
treatment of cutaneous leishmaniasis in the state of Rio de Janeiro (RJ).
METHODS
Between 2008 and 2011, 60 patients with CL were observed. They 
were all over 13 years, participants in a controlled clinical trial, blind 
and in phase III of equivalence between the standard treatment scheme 
(20 mg Sb5+/kg/day for 20 consecutive days) and other MA alternative 
schemes, ongoing at the Evandro Chagas Research Institute - IPEC, 
Oswaldo Cruz Foundation, Rio de Janeiro. The test was registered 
at the site http://clinicaltrials.gov - Identifier: NCT01301924, and 
approved by the Ethics Committee on Research/IPEC under the number 
0055.0.0009.000-07. 
Initially, sixty individuals were randomly distributed, 15 in each of 
the treatment groups by intramuscular administration of MA. From the 
initial 60 CL patients, three were excluded, because they did not make 
the adherence evaluation: two of them refused to participate in the 
adherence evaluation, and the other one died. The 57 remaining patients 
were allocated as follows: 20 mg Sb5+/kg/day for 20 consecutive days (n = 
13), 20 mg Sb5+/kg/day in two intermittent series of 10 days interspersed 
by a 10-day interval (n = 14), 5 mg Sb5+/kg/day for 30 consecutive days 
(n = 15) and 5 mg Sb5+/kg/day in three intermittent series interspersed 
by 10-day intervals (n = 15). For analysis purposes, the patients were 
grouped in high (20 mg Sb5+/kg/day) and low (5 mg Sb5+/kg/day) doses; 
and consecutive and intermittent doses.
At the time of medicine administration, the patients were interviewed 
with the aid of a standardized questionnaire for socioeconomic data 
collection (gender, age, coming from an endemic area or not, people 
co-habiting in the same house, people sleeping in the same room, marital 
condition, level of education, personal and family monthly income, 
smoking habits, alcohol and drug consumption, who administers the 
medicine and their instruction level, whether the medicine affects the 
daily life) and assessment of satisfaction with treatment, IPEC and the 
healthcare team.
Clinical healing was defined as lesion scarring with no recurrence 
within a year after treatment. Monitoring abandonment was defined as 
the patient not returning to the appointments provided during the first 
year after the beginning of the treatment. 
Adherence to therapy was evaluated according to four criteria 
(counting of vial surplus, monitoring card, Morisky test and modified 
Morisky test).
Counting of vial surplus: The vials for the treatment were supplied 
with a small surplus, and the patient was advised to return the vials that 
were not used at the next appointment. Patients were considered adherent 
when they delivered vials in equal or lower number than expected and 
non-adherent when they delivered a greater number of vials. 
Monitoring card: Patients registered date and time of each dose in 
the monitoring card and requested the signature of the person who applied 
it. The patients that returned the card completely filled out, with intervals 
between doses not greater than three days, were considered adherent. 
Morisky test: it was applied at the end of the treatment and comprised 
four dichotomous questions (each negative answer received one point); 
and a patient was considered adherent if they got four points and non-
adherent when they got any other lower value19,20. The four questions of 
the Morisky test are: 1 - Have you ever forgotten to take your medicine? 
2 - Sometimes do you forget to take your medicine? 3 - When you feel 
better, do you sometimes stop taking your medicine? 4 - At times, if 
you feel worse when you take your medicine, do you stop taking them? 
Modified Morisky test: in the modified version, the 2nd question 
regarding the schedule of taking the medicine was not considered, and 
a patient was considered adherent when they got three points and non-
adherent, any lower value. 
In the exploratory analysis, the simple frequencies of the qualitative 
variables and the median with interquartile range of the quantitative 
variables were calculated. The association of adherence (vial counting, 
Morisky test, modified Morisky test and monitoring card) with the socio-
demographic and clinical variables and the treatment groups (high doses - 
20 mg Sb5+/kg/day - or low - 5 mg Sb5+/kg/day; consecutive or intermittent 
doses) was evaluated by the Fisher’s exact test. The Mann-Whitney test 
was used to assess the distribution difference of the quantitative variables 
in relation to the adherence variable. 
The degree of concordance between the methods of adherence 
determination was evaluated by the simple Kappa index and categorized 
according to LANDIS & KOCH12 as κ: < 0 (non concordance), κ: 0-0.19 
(poor concordance), κ: 0.20-0.39 (fair concordance), κ: 0.40-0.59 
(moderate concordance), κ: 0.60-0.79 (substantial concordance), 
κ: 0.80-1.00 (perfect concordance). The adopted level of significance 
for all the statistical tests was 5%. The Statistical Package for the Social 
Sciences (SPSS) version 16.0 was used for data analysis. 
RESULTS
The median age was 40 years (minimum of 15 and maximum of 71), 
predominantly men (68.4%), white (61.4%), single or widowed (54.4%), 
education to 1st grade school (57.9%), monthly family income between 
one and five minimum wages (each minimum wage corresponding to US$ 
321.77)3 and resident in RJ endemic areas (86%). There was a median of 
three family members, ranging from one to eight members, with a median 
of two people sleeping in the same room (minimum one and maximum 
six). Regarding habits, it was found that the patients were 84.1% non-
smokers, 93.0 non-users of illicit drugs and 57.9 % non-users of alcohol. 
MA administration was done by health care providers in 71.9% of 
the cases, 68.4% of them with a college degree. The distance between 
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home and the administration site was less than 10 km in 82.5% of cases, 
and 63.2 % of the patients reported that the treatment did not affect their 
daily life. 
All patients reported satisfaction with treatment, IPEC and the 
medical staff.
88.2% of the patients were healed. We observed 82.1% adherence 
to treatment by controlling returned vials, 86.0% by the monitoring 
card, 66.7% through the Morisky test and 86.0% through the modified 
Morisky test. 
There was a greater adherence of the group that received low doses 
when evaluated by the modified Morisky test (p-value = 0.021). The 
comparisons between adherence assessment methods and high and 
low dose schemes, and between consecutive and intermittent doses are 
shown in Table 1. 
We did not observe a significant correlation between the qualitative 
variables and adherence to treatment. We observed that there were a 
significantly greater number of persons sleeping in the same room among 
those that did not adhere to treatment, by the four adherence evaluation 
methods (Table 2). No significant correlation was observed between 
adherence to treatment and the other quantitative variables assessed: age 
and number of family members (Table 2). 
The degree of concordance among the adherence evaluation criteria 
measured by the Kappa index was considered satisfactory (substantial and 
perfect concordance), for most criteria, except between the Morisky test 
and the monitoring card, which presented poor concordance (Table 3). 
DISCUSSION
Factors associated with adherence of patients to different treatment 
schemes were evaluated during a clinical trial for CL treatment with 
MA, using a socioeconomic and evaluation of satisfaction with treatment 
questionnaire, return of non-used medicine vials, monitoring card, 
Morisky test and modified Morisky test. We did not find similar studies 
Table 1
Comparison between adherence to high dose (20 mg Sb5+/kg/day) and low dose (5 mg Sb5+/kg/day) schemes; and consecutive or intermittent administration
Adherence
Dose Type of administration




n %  n  % n % n %
Surplus vial Counting 20 74.1 26 90 0.171 22  78.6 24 86 0.485
Morisky test 17 63 21 70 0.574 18  64.3 20 69 0.708
Modified Morisky test 20 74.1 29 97 0.021 24  85.7 25 86 1.000
Monitoring Card 23 85.2 26 87 1.000 23  82.1 26 90 0.470
n = number of patients adherent to treatment. p = p-value. In bold, p-significant value.
Table 3
Concordance among adherence to treatment assessment methods in each 
treatment scheme in the clinical trial 
Adherence Kappa Index (κ)
Degree of 
Concordance*




Surplus vial counting and 
Modified Morisky test 0.736
Substantial 
Concordance




Surplus vial counting and 
Morisky test 0.351 Fair Concordance
Morisky test and 
Monitoring card 0.123 Poor Concordance
Note: *Classification according to Landis JR, Kock GG. 1977.
Table 2
Assessment of the distribution difference of the quantitative variables, in relation to the adherence variable by the Mann-Whitney test
Adherence methods
Family members sleeping in the same room 
Adherence Non-adherence
p-value
Median Minimum Maximum Median Minimum Maximum
Surplus vial counting 2.00 1 4 3.00 2 6 0.001
Morisky test 2.00 1 4 2.00 1 6 0.037
Modified Morisky test 2.00 1 4 3.00 2 6 0.001
Monitoring card 2.00 1 6 2.50 2 4 0.012
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in literature, comparing adherence to CL treatment with MA measured 
using different assessment methods. 
Similar to our results, the variable gender has not shown, in the 
literature, a significant relationship with adherence to therapy33. 
Regarding the socioeconomic factors, the correlation found between 
adherence assessed by all the methods studied and a higher number of 
family members sleeping in the same room may be related to a more 
precarious economic condition of the patients. The correlation between 
adherence and socioeconomic characteristics of the patients has been 
widely studied in other infectious diseases, and contradictory results that 
may vary with the methods used have been found5,15,25.
Although the use of medication did not alter the daily life of most 
patients, this occurred in 40% of them, which is understandable, 
considering that it is a parental medication that needs a qualified health 
professional to administer it, forcing the patient to leave home daily. 
It has been reported that patients present higher adherence levels to 
treatments when the administration is simple and the recommendations 
are easy to understand, they are short-term treatments and the patients 
do not significantly alter their daily lives7. On the other hand, adherence 
studies through intravenous (IV) administration of MA would require 
hospitalization or a day-hospital base, a condition that we cannot 
afford for all CL patients in Rio de Janeiro. We could, however, assume 
that adherence to treatment would be higher with IV MA, due to the 
discomfort associated with the use of intramuscular medication, and to 
the hospitalization itself21,27. 
The high adherence level observed in the present study can be 
partially explained by the voluntary participation in the clinical trial 
and the good relationship between patient and health care providers 
at IPEC, as proved in the assessment questionnaire of satisfaction 
with care and the hospital. The good relationship between health care 
providers and patients is increasingly recognized as a determinant for 
adherence to therapy16,24.
A study of cultural and socioeconomic conditions showed that, 
despite the lower education and income of the population treated for 
ATL, the abandonment percentage was lower (1.6%), when compared 
to percentages previously reported for the Metropolitan Region of Belo 
Horizonte (25%)25. This result is compliant with the good adherence 
results of the present study, where the good relationship between patients 
and the health care team, as well as the voluntary participation, helped 
to obtain it. 
Higher abandonment frequency in patients with a continuous 
treatment scheme, when compared to intermittent schemes of MA, 
has already been described2. Although our study did not present 
correlation between adherence and intermittent or continuous schemes, 
a significantly higher adherence was observed in the group that received 
low doses, when compared to the group that received high doses, when 
assessed by the modified Morisky test. The patients who received low 
doses may have presented better adherence, because the administration 
was simpler, there were fewer side effects and consequently lower 
modification of the daily life7. Especially for the elderly, the use of 
lower doses is recommended since the toxic effects of antimony are 
less pronounced and, consequently, the adhesion to therapy is greater23. 
Besides, it can be assumed that the refusal of two patients to respond 
to adherence assessment methods suggests that poor adherence is 
associated with a high dose. 
It is believed that it is possible to monitor adherence to the prescribed 
treatment by counting the medication, as previously described in 
tuberculosis15. The medicine vial counting allows determination of the 
number of vials used, however, it is a method that requires collaboration 
and is subject to manipulation by the patient. It may also overestimate 
adherence, because the fact of returning the correct number of surplus 
vials, or less, does not necessarily ensure that the medication was correctly 
administered by the patient.
The monitoring card is a method that tends to underestimate 
adherence, because it needs the collaboration of the patient and the 
administrator: if, for some reason, it does not contain the signature of the 
administrator or if it is not completely filled out, the patient is considered 
non-adherent, even if they received the correct medication.
The Morisky test19,20 tends to overestimate non-adherence, as opposed 
to what is expected from indirect methods and does not give the patient 
the opportunity to express their difficulties and understand the treatment13. 
In the Morisky test, carelessness regarding medication time has been 
the answer most frequently given by the patients. Being a deposit drug, 
in which the therapeutic effect of antimony seems to be supplied by 
the fraction accumulated in the tissues4,8,17,26,32 carelessness, regarding 
the time when the medication is taken, it would not significantly affect 
adherence, if the daily administrations followed the schedule prescribed 
for the patient. When the modified Morisky test was applied, a significant 
correlation between adherence and low dose of meglumine antimoniate 
was obtained. 
A study using the Morisky test showed low adherence level in leprosy 
treatment, indicating that patients did not have adequate knowledge of 
the principles of multidrug therapy, despite claiming to be familiar with 
leprosy and its therapy14. The Morisky test helps to identify the main 
reasons why patients do not adhere properly to treatment, which can 
help health care providers to find efficient solutions to solve adherence 
problems. 
A study that assessed adherence to tuberculosis treatment by 
providing medication kits and the monitoring card revealed that counting 
the daily kits allowed assessing adherence to treatment15. In the present 
study, among the various methods, there was greater concordance 
between the vial counting and the monitoring card, although the first 
overestimates and the second underestimates adherence to treatment. 
When we applied the modified Morisky test, we observed a substantial 
concordance with the method of vial return and moderate with the 
monitoring card, thus suggesting that the first was adequate and simple 
to assess adherence of this group of patients. 
We found a correlation between non-adherence to CL treatment 
with MA, assessed by various methods, and a higher number of family 
members sleeping in the same room. The assessment by the modified 
Morisky test showed better adherence in the group that received low 
doses of MA, than in the group that received high doses. Due to the good 
performance and simplicity of the method, when compared to other tests, 
we suggest the use of the modified Morisky test to assess adherence to 
CL treatment with MA.
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RESUMO
Fatores associados à adesão a diferentes esquemas de tratamento 
com antimoniato de meglumina em ensaio clínico para 
leishmaniose cutânea
O desfecho favorável ao tratamento de uma enfermidade é 
influenciado pela adesão à terapia. Objetivamos avaliar fatores associados 
à adesão ao tratamento dos pacientes incluídos em ensaio clínico de 
equivalência entre o esquema de tratamento padrão e alternativos com 
antimoniato de meglumina (AM) no tratamento da leishmaniose cutânea 
(LC) no estado do Rio de Janeiro. Entre 2008 e 2011, 57 pacientes com 
LC foram entrevistados através de questionário para coleta de dados 
socioeconômicos. Para monitorização da adesão foram utilizados 
os seguintes métodos: contagem de ampolas excedentes, cartão de 
acompanhamento, teste de Morisky e teste de Morisky modificado 
(sem a pergunta referente ao horário). Observou-se adesão de 82,1% 
(devolução de ampolas), 86,0% (cartão de acompanhamento), 66,7% 
(teste de Morisky) e 86,0% (teste de Morisky modificado). Houve 
forte concordância entre o método contagem de ampolas e cartão de 
acompanhamento, bem como teste de Morisky modificado. Verificou-se 
associação significativa entre maior adesão ao tratamento e baixa dose 
de AM, bem como com menor número de pessoas dormindo no mesmo 
quarto. Recomendamos a utilização do teste de Morisky modificado 
na avaliação da adesão ao tratamento da LC com AM por ser método 
simples e com bom desempenho quando comparado aos outros testes.
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